Study wrapper · #987
2025 FDA TIDES (Peptides and Oligonucleotides) Harvest.
AlShaer D, Al Musaimi O, Albericio F, et al. Pharmaceuticals (Basel, Switzerland). 2026.
DOI: 10.3390/ph19020244PubMed: 41754785
Editor's note
A review of 2025 FDA peptide and oligonucleotide approvals that documents elamipretide's approval for Barth syndrome, a specific inherited condition. A notable regulatory milestone for the peptide, though the approval is narrow and disease-specific. Useful context for SS-31 coverage.
Plain-language abstract
This review of 2025 FDA-approved peptide and oligonucleotide drugs notes that elamipretide became the first approved therapy for Barth syndrome.
Related coverage
Supported
Oral Colon- and Mitochondria-Targeted Nanoparticles Alleviate Ulcerative Colitis by Reeducating Macrophage Polarization via SIRT3/FOXO3a-Mediated Mitochondrial Restoration.
Journal of gastroenterology and hepatologyn=——2026
Mixed
Seawater immersion reshapes the temporal dynamics of traumatic brain injury and reveals mitochondrial oxidative stress as a modifiable therapeutic target.
Experimental neurologyn=——2026
Supported
Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.
Brain, behavior, and immunityn=——2026